Search results
Is This a Setback for Moderna?
Motley Fool via Yahoo Finance· 2 days agoSo some healthcare providers may prefer the safety profile of the...reason alone. It's also important to keep in mind that the RSV market size is $10...
"FLiRT" COVID variants are now more than a third of U.S. cases. Scientists share what we know about...
CBS News· 6 days agoMore than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 4 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
NewMediaWire via Yahoo Finance· 2 days agoPresented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven...
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop...
CNBC· 7 days agoA health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization...
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
Benzinga· 4 days agoFollowing the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after vaccination with ...
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights
GuruFocus.com via Yahoo Finance· 6 days agoThe anticipated mid-2024 pivotal readout of the Phase 3 AFFINE trial, a collaboration with Pfizer for hemophilia A treatment, could potentially lead to regulatory submissions ...
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 4 days agoThe intent is to position PRX-115 as a direct competitor in the market for uncontrolled gout patients. Q: How do the pharmacokinetic (PK) levels of PRX-115 trend over the observed three ...
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into F
Guru Focus· 6 days agoSangamo Therapeutics Inc (SGMO, Financial), a leader in genomic medicine, disclosed its 8-K filing on May 9, 2024, revealing detailed insights into its first quarter financials and recent strategic ...
Amid Biotech Pitfalls, This Stock Has Outperformed Nvidia in the Last 3 Months | Investing.com UK
Investing.com· 3 days agoBiotech stocks, especially of smaller companies, are notoriously risky investment exposures. Because...
